Phase 2 clinical study of evaluation of efficacy of switch to eribulin chemotherapy in patients with locally advanced breast cancer or metastatic breast cancer who are not responsive to combination regimen of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) and continuation of TAC chemotherapy in responding patients to TAC

Phase 2 clinical study of evaluation of efficacy of switch to eribulin chemotherapy in patients with locally advanced breast cancer or metastatic breast cancer who are not responsive to combination regimen of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) and continuation of TAC chemotherapy in responding patients to TAC - To evaluation of efficacy of switch to eribulin chemotherapy in breast cancer patients who are not responsive to TAC and continuation of TAC in responding patients to TAC

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015838

Enrollment

Registered

2014-12-03

Start date

2014-12-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced and/or metastatic breast cancer patients

Interventions

18Ffluorodeoxyglucose positron emission tomography combined with computed tomography and diffuse optical spectroscopy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patinet who got informed consent on paper patients with 20 year old or more Invasive breast cancer was confirmed by pathology Patients with locally advanced or metastatic breast cancer Tumor can be measured by RECIST criteria

Exclusion criteria

Exclusion criteria: Patients who do not have informed consent on paper Patients who have uncontroled severe diabetes, infection , or other malignancy Patients whom doctor consider this treatment are suitable for.

Design outcomes

Primary

Measure	Time frame
To evaluate radiological response to eribulin in TAC non-responding patients	—

Countries

Japan

Contacts

Public ContactShigeto Ueda

Saitama Medical Univeristy International Medical Center Dept of breast oncology

syueda@saitama-med.ac.jp81-42-984-4670

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026